St Louis, MO Clinical Trials Report — June 2026

For residents of St Louis, MO, looking to engage with cutting-edge medical research, June 2026 presents a critical window of opportunity, particularly for trials nearing their enrollment deadlines. Across St Louis, a total of 1,348 clinical trials are currently recruiting across 420 research facilities, offering diverse avenues for participation.

A significant number of studies are closing soon, making prompt action essential for interested individuals. There are 64 trials slated to conclude enrollment within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 10 of these rapidly closing studies are still actively seeking participants without specific health conditions.

Act Now: Trials Nearing Their Close

Patients managing specific health conditions also have limited time to join research before enrollment windows close. Trials focused on various conditions are among those with impending deadlines:

• Solid tumor (2 trials)
• Prostate cancer (2 trials)
• Lupus nephritis (2 trials)
• Quality of life (2 trials)
• Alzheimer disease (2 trials)
• Venous leg ulcer (2 trials)
• Endometrial cancer (2 trials)
• Fallopian tube cancer (2 trials)
• Neoplasms by histologic type (2 trials)
• Acute myeloid leukemia (1 trial)

These trials represent vital research efforts, and participation now could contribute significantly to advancements in these areas.

New Research Opportunities in St Louis

This month, St Louis, MO, saw a notable increase in new research, with 24 new trials opening. This is a significant jump from the 14 trials that launched in May 2026, indicating a growing research landscape in the city.

The new trials are exploring a range of conditions, with a strong focus on metabolic health. The most frequently studied conditions among the new trials include:

• Obesity (3 trials)
• Overweight (3 trials)
• Chronic weight management (2 trials)
• Advanced breast cancer (1 trial)
• Breast cancer (1 trial)
• Caffeine (1 trial)
• Attention (1 trial)
• Diabetic foot ulcers (DFUs) (1 trial)
• Chronic wounds (1 trial)
• Cognitive performance (1 trial)

Drug trials account for the largest share of new studies, with 17 new drug trials, followed by 3 device trials and 2 behavioral studies. Academic institutions, notably Washington University School of Medicine, are leading the charge, sponsoring 8 of the new trials. Industry sponsors like Kallyope Inc., Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, and Novo Nordisk A/S are also driving significant research efforts.

Highlighting Major New Trials

June brings several high-profile new trials to St Louis, including significant Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges:

• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics is initiating a notable Phase 3 study, NCT07654361, "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)." This pivotal, multicenter, global, randomized, placebo-controlled, double-blind study aims for 3,600 participants to investigate the long-term efficacy, safety, and tolerability of aleniglipron once daily compared with placebo, when used in combination with a reduced-calorie diet.
• Also from Gasherbrum Bio, Inc., NCT07654374, "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)," is a Phase 3 randomized, double-blind, placebo-controlled study involving 1,100 participants. It will evaluate the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and Type 2 Diabetes Mellitus.
• Kallyope Inc. is sponsoring NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine." This double-blind, randomized, multicenter, outpatient Phase 3 evaluation aims for 1,800 participants to assess the efficacy, safety, and tolerability of elismetrep compared with placebo in the acute treatment of migraine.
• Another study from Kallyope Inc. is NCT07674654, "A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine." This Phase 3 study seeks 1,000 participants to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks.
• AstraZeneca is leading NCT07662044, "A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus." This Phase 3 study aims for 800 participants to evaluate the efficacy, safety, and tolerability of elecoglipron alone or in combination with dapagliflozin in adults with Type 2 Diabetes Mellitus inadequately managed with lifestyle changes or other glucose-lowering treatments.
• RTI International is sponsoring NCT07625579, "Collaboration for Down Syndrome Progress (CDP)." This long-term study follows 1,400 people with Down syndrome of all ages to better understand their health, development, and everyday experiences over time.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research in St Louis. Of the 24 new trials launched this month, 3 are actively seeking healthy volunteers. More broadly, a total of 114 clinical trials are currently recruiting healthy participants across St Louis, providing numerous avenues for those interested in supporting medical research.

St Louis's Leading Research Facilities

St Louis is home to prominent research institutions that consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Washington University School of Medicine (429 trials)
• Washington University (126 trials)
• Mercy Hospital Saint Louis (94 trials)
• Mercy Hospital South (84 trials)
• Siteman Cancer Center-South County (84 trials)
• Missouri Baptist Medical Center (81 trials)
• Siteman Cancer Center at Christian Hospital (78 trials)
• Washington University in St. Louis (70 trials)
• Research Site (51 trials)
• Mercy Infusion Center - Chippewa (36 trials)
• Cardinal Glennon Children's Medical Center (24 trials)
• St. Louis Children's Hospital (22 trials)

These institutions offer a broad spectrum of research, with Washington University and its affiliated medical centers leading in the sheer volume of studies, covering diverse medical fields and specialized areas like cancer research at the Siteman Cancer Centers.

Broadening Your Search: Nearby Options

While St Louis offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Missouri. Cities with active trials include Kansas City (9 trials), Springfield (7 trials), City of Saint Peters (7 trials), Hazelwood (4 trials), Chesterfield (2 trials), Columbia (2 trials), North Kansas City (1 trial), and Jefferson City (1 trial).

Participation in clinical trials is open to a diverse range of individuals. Of the 24 new trials launched this month, 23 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 2 new trials include children, and 1 is male-only. As St Louis continues to be a hub for medical innovation, the opportunities for individuals to contribute to the future of healthcare remain robust and varied.